Krug, S., Roth, L., Hämmerle, M., Rosendahl, J., Kleeff, J. H., & Michl, P. (2022). The impact of atezolizumab and bevacizumab in hepatocellular carcinoma with activated ß-catenin signaling. Cancer reports, 5(3), . https://doi.org/10.1002/cnr2.1493
Chicago-Zitierstil (17. Ausg.)Krug, Sebastian, Laura Roth, Monika Hämmerle, Jonas Rosendahl, Jörg H. Kleeff, und Patrick Michl. "The Impact of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma with Activated ß-catenin Signaling." Cancer Reports 5, no. 3 (2022). https://doi.org/10.1002/cnr2.1493.
MLA-Zitierstil (9. Ausg.)Krug, Sebastian, et al. "The Impact of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma with Activated ß-catenin Signaling." Cancer Reports, vol. 5, no. 3, 2022, https://doi.org/10.1002/cnr2.1493.